Use of Non-GAAP Measures Page 3 PolyOne Commodity to Specialty Transformation • Volume driven, commodity producer • Heavily tied to cyclical end markets • Performance largely dependent on non- controlling joint ventures 2000-2005 2006 - 2009 2010 – 2014 2015 and beyond • Steve Newlin appointed, Chairman, President and CEO • New leadership team appointed • Implementation of four pillar strategy • Focus on value based selling, investment in commercial resources and innovation to drive transformation • 18 consecutive quarters of double- digit adjusted EPS growth • Shift to faster growing, high margin, less cyclical end markets • Key acquisitions propel current and future growth, as well as margin expansion • Established aggressive 2015 targets • Continue specialty transformation • Targeting $2.50 Adjusted EPS by 2015, nearly double 2013 EPS • Drive double digit operating income and adjusted EPS growth Page 4 2013 Revenues: $3.8 Billion End Markets 2013 Revenues: $3.8 Billion Page 5 PolyOne At A Glance United States 67% Europe 14% Canada 7% Asia Latin America Specialty 54% PP&S 18% Distribution 28% $13 $31 $46 $46 $92 $96 $122 $195 $0 $50 $100 $150 $200 2006 2007 2008 2009 2010 2011 2012 2013 Specialty Operating Income Building & Construction 13% Industrial 12% Transportation 18% Wire & Cable 9% Packaging 16% Consumer 10% HealthCare 11% Appliance Electronics & Electrical 5% Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 62% 64% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2013 Q1 2014 2015 % o f O pe ra tin g In co m e* JV's Performance Products & Solutions Distribution Specialty 65-75% Specialty OI $5M $46M $87M $195M $60M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 6 Confirmation of Our Strategy The World’s Premier Provider of Specialized Polymer Materials, Services and Solutions Specialization Globalization Operational Excellence Commercial Excellence Page 7 -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% 450.00% 550.00% PolyOne S&P 500 Strategy and Execution Drive Results $0.12 $0.27 $0.21 $0.13 $0.68 $0.82 $1.00 $1.31 '06 '07 '08 '09 '10 '11 '12 '13 ‘06-‘13 EPS CAGR = 41% EPS Share Price vs. S&P 500 All time high of $39.55 May 13th, 2014 Page 8 2006 Q1 2014 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 13.8% 12 – 16% Global Specialty Engineered Materials 1.1% 11.6% 12 – 16% Designed Structures & Solutions -- 6.5% 8 – 10% Performance Products & Solutions 5.5% 7.7% 9 – 12% Distribution 2.6% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 64% 65 – 75% 3) ROIC* 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 42% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 9 Bridge to $2.50 Adjusted EPS by 2015 2015 EPS: $2.50 2013 EPS: $1.31 Continued Gross Margin Expansion Mergers & Acquisitions Spartech Accretion Incremental share buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Several Levers to Drive Growth Mid single digit revenue CAGR Page 10 Innovation Drives Earnings Growth *Percentage of Specialty Platform revenue from products introduced in last five years Page 11 $20 $53 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 43.0% 2006 2013 Healthcare Consumer Packaging and Additive Technology Transportation Page 12 Unique and Innovative Solutions https://www.dropbox.com/sh/dwe4t8aacvhb8ui/uD3p_bdglP/Presentation revise pics/GLS Beverage can closure XO 2.jpg https://www.dropbox.com/sh/dwe4t8aacvhb8ui/-YgkycKypw/Anti-Counterfeiting release & images/GN1979.JPG 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of March 31, 2014 Debt Maturities & Pension Funding – 3/31/14 Net Debt / EBITDA* = 1.9x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of March 31, 2014 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 3/31/2014 Page 13 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return $0.16 $0.20 $0.24 $0.32 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend  Expanding our sales, marketing, and technical capabilities  Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin  Synergy opportunities  Adjacent material solutions  Repurchased 1.4 million shares in Q1 2014  Repurchased 6.4 million shares since April 2013  13.6 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends  Investing in operational and LSS initiatives (including synergy capture) Manufacturing alignment Page 14 The New PolyOne: A Specialty Growth Company Why Invest In PolyOne?

Page 102 Critical Imperatives – Medium to Long Term • Continue cultural and paradigm shift from commodity compounder to collaborative formulator as One PolyOne • Accelerate innovation and leverage megatrends to improve our mix of business with higher-margin improve our mix of business with higher-margin specialty products • Increase specialty contribution and advance globalization via acquisitions • Drive relentless execution and creative innovation as key competitive differentiators Page 103 2011 Proforma ColorMatrix 2015 Target “Where we are” “Where we expect to be” 1) Operating Income % Specialty 8.9% PP&S 7.2% 12 – 16% 9 – 12% Elevating our Expectations and Yours PP&S 7.2% Distribution 5.6% 2) Specialty Platform % of Operating Income 50% 3) ROIC* (after-tax) 10% 4) Adjusted Annual EPS Growth 3 yr CAGR = 71% 9 – 12% 6 – 7.5% 65 – 75% 15% Double Digit Expansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 104

PHYSICAL/CHEMICAL PROPERTIES CATEGORY DETAIL EC Number 236-675-5 CAS Number 13463-67-7 Name Subclass 1 Titanium Dioxide (TiO2) Structural Formula O======Ti====== O PROPERTY DETAIL Physical State Solid Form Crystalline Color White Odor Odorless Melting Point 1560–1843°C Boiling Point 3,000°C Bulk Density 3.9 g/mL at 25°C Water Solubility Immiscible HEALTH EFFECTS HUMAN HEALTH SAFETY ASSESSMENT Consumer Based on available data, TiO2 is not a hazardous substance. Health risks through exposure to TiO2 in its powdered form are presumed to be extremely low since TiO2 is typically fully incorporated into the end product in which it is used. EXPOSURE HUMAN HEALTH SAFETY ASSESSMENT Human Health The substance is used in industrial settings only.

CATEGORY DETAIL EC Number 215-609-9 CAS Number 1333-86-4 Name Subclass 1 Carbon Black Structural Formula CHEMICAL IDENTITY H | C||||HH H HEALTH EFFECTS HUMAN HEALTH SAFETY ASSESSMENT Consumer Overall, as a result of the detailed epidemiological investigations, no causative link between Carbon Black exposure and cancer risk in humans has been demonstrated. Worker Several epidemiological and clinical studies of workers in the Carbon Black production industries show no evidence of clinically significant adverse health effects due to occupational exposure to Carbon Black. Toxicity for Reproduction PROPERTY DETAIL Physical State Solid Form Powder/ Beads Color Black Odor Odorless Melting Point 3550°C Boiling Point 500–600°C Partition Coefficient: N-octanol/Water Not Applicable Bulk Density 1.7-1.8 g/cm3 (20°C) Water Solubility Insoluble Self-ignition Temperature >284°F Flammability >45 s Explosiveness 50 g/m3 PHYSICAL/CHEMICAL PROPERTIES EXPOSURE HUMAN HEALTH SAFETY ASSESSMENT Human Health Carbon Black, when generally used as noted above is bound into a matrix.

Health and Safety • Implement appropriate processes and procedures to ensure that human health and safety are at the forefront of your actions. Comply with all applicable environmental, health, safety, and security regulations. Version: May 2025 mailto:sourcing@avient.com Health and Safety Environment Social Ethics and Governance Management Systems

When designing a medical device, selecting a material that will last and perform well under harsh conditions has never been tougher. Currently, concerns over healthcare-associated infections (HAIs) have led many medical facilities to respond by disinfecting equipment surfaces more frequently using harsher disinfectants. Versaflex™ HC thermoplastic elastomers can enhance ergonomics in medical devices by adding a soft touch and improved grip.

Mevopur™ Healthcare Colorants and Formulations Special Effect Colorants for Healthcare Devices and Pharmaceutical Packaging Self-administered medication, for example via pen devices and inhalers, has been the norm for many years. Ingredients used in the Mevopur™ portfolio have been tested to industry standards that support applications in both medical devices and pharmaceutical packaging.* KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified manufacturing sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Non-phthalate and formulated without animal-derived substances • Available as pre-colored formulation or concentrate and for use in different polymers REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU** APPLICATION BULLETIN * Design note: Effect colors require careful consideration of part design and polymer flow paths to minimize visible flow lines. It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device with all applicable laws and regulations, including the suitability of all raw materials and components used for its manufacture.

Mevopur™ Healthcare Functional Additives Laser Marking Additives for Medical Devices and Pharmaceutical Packaging Laser marking offers several advantages compared to other marking technologies. Potential applications include graduation markings for dose-dials, syringes and droppers, and serialization/coding (e.g., UDI) for medical devices and pharmaceutical packaging. It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device with all applicable laws and regulations, including the suitability of all raw materials and components used for its manufacture.

Avient Colorants Sweden AB Järnyxegatan 7 Box 9053 200 39 Malmö Sweden Scope Avient CAI Design and manufacture of colour and additive concentrates and specialty compounds for the Healthcare and Medical device market. Normative base EN ISO 13485:2016 Medical devices – Quality Management System Reg. no. 37081 Validity 01.03.2022 – 28.02.2025 Issue 01.03.2022 Swiss Made Swiss Association for Quality and Management Systems (SQS) Bernstrasse 103, 3052 Zollikofen, Switzerland sqs.ch F.

Important information about the health, safety and environmental impacts of Avient products. Important information about the health, safety and environmental impacts of Avient products.